709. Nieuwboer A, De Weerdt W, Dom R, Truyen M, Janssens L, Kamsma Y. The effect of a home physiotherapy program for persons with Parkinson's disease. J Rehabil Med 2001; 33(6):266-272.
710. Stozek J, Rudzinska M, Longawa K, Szczudlik A. [The effect of the complex rehabilitation on posture and gait in Parkinson disease]. Neurol Neurochir Pol 2003; 37 Suppl 5:67-81.
711. Morris ME. Movement disorders in people with Parkinson disease: a model for physical therapy. Phys Ther 2000; 80(6):578-597.
712. Reuter I, Mehnert S, Sammer G, Oechsner M, Engelhardt M. Efficacy of a multimodal cognitive rehabilitation including psychomotor and endurance training in Parkinson's disease. J Aging Res 2012; 2012:235765.
713. van Eijkeren, F. Nordic Walking Improves Mobility in Parkinson’s Disease / F. van Eijkeren, R. Reijmers, M. Kleinveld [et al.]// Mov Disord. – 2008. – Vol. 23, № 15. – P. 2239–2243.
714. Atterbury, E. Balance training in individuals with Parkinson's disease: therapist- supervised vs. home-based exercise programme/ E. Atterbury, E. K. Welman// Gait Posture. – 2017. – Vol.55. - P.138-144.
715. Rochester, L. Targeting dopasensitive and dopa-resistant gait dysfunction in Parkinson’s disease: selective responses to internal and external cues/ L. Rochester, K. Baker, Nieuwboer, A. D. Burn// Mov Disord. - 2011. - Vol.26. - P.430–435.
716. Hausdorff, J.M. Gait dynamics, fractals and falls: finding meaning in the stride-to- stride fluctuations of human walking/ J.M. Hausdorff // Hum Mov Sci. -2007. - Vol.26. - P.555– 589.
717. Frazzitta, G. Rehabilitation treatment of gait in patients with Parkinson’s disease with freezing: a comparison between two physical therapy protocols using visual and auditory cues with or without treadmill training/ G. Frazzitta, R. Maestri, D. Uccellini [et al.] // Mov Disord. - 2009. - Vol.24. - P.1139–1143.
718. Donovan, S. Laserlight cues for gait freezing in Parkinson’s disease: an open-label study/S. Donovan, C. Lim, N. Diaz [et al.] // Parkinsonism Relat Disord. -2011. - Vol.17. - P. 240–245.
719. Reuter, I. Effects of a flexibility and relaxation programme, walking, and nordic walking on Parkinson's disease/I. Reuter, S. Mehnert, P. Leone [et al.] // J Aging Res. -2011. - P. 1-18.
720. Kalf, H., de Swart, B., et al. Guidelines for Speech-Language Therapy in Parkinson’s Disease Nijmegen (The Netherlands); Miami (U.S.A.): ParkinsonNet (The Netherlands); National Parkinson Foundation (U.S.A.), (2011), 1-137.
721. Deuschl, G, Herzog J, Kleiner-Fisman G, Kubu C , M. Lozano, E. Lyons ,Maria C. Rodriguez-Oroz ,Filippo Tamma ,Alexander I. Tröster ,Jerrold L. Vitek , Jens Volkmann J, Voon V. Deep brain stimulation: Postoperative issues//Mov Disord. 2006 Jun;21 Suppl 14:S219- 37.
722. Приказ Минздрава России от 15.11.2012 №926н «Об утверждении Порядка оказания медицинской помощи взрослому населению при заболеваниях нервной системы» (зарегистрирован в Минюсте России 23.01.2013 №26692)
733. Приказ Министерства здравоохранения Российской Федерации от 28 сентября 2020 г. N 1029н «Об утверждении перечней медицинских показаний и противопоказаний для санаторно-курортного лечения» http://publication.pravo.gov.ru/Document/View/0001202010270044.
734. Trosch RM et al. Clozapine use in Parkinson’s disease: a retrospective analysis of a large multicentered clinical experience//Movement disorders.-1998.-T.13.-№3.-C.377-382.
735. Катунина, Е.А. Применение препарата допа и ее производные в лечении болезни Паркинсона/Е.А. Катунина, Г.Н. Авакян, Ю.Н. Бездольный//Эффективная фармакотерапия.-2010.-№17.-С.12-19.
736. Cutsforth JK, Low PA Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer Neurol Ther. 2019 Dec; 8(2): 307–324 doi: 10.1007/s40120-019-00152-9
737. ThorpyMJ. Sleep disorders in Parkinson’s disease. Clin Cornerstone. 2004;6 Suppl 1A:S7-15. doi: 10.1016/s1098-3597(04)90013-0. PMID:15259535.
738. Нодель М.Р., Яхно Н.Н. Утомляемость при болезни Паркинсона. Неврологический Журнал. 2017;5:244-251.
739. Razmy A., Lang A.E., Shapiro C.M. Predictors of impaired daytime sleep and wakefulness in patients with parkinsons disease treated with ergot vs nonergot dopamine agonists. Arch. Neurol.2004; 61: 97–102.
740. Metzer WS, Paige SR, Newton JE. Inefficacy of propranolol in attenuation of drug- induced parkinsonian tremor. Mov Disord. 1993;8(1):43-6. doi: 10.1002/mds.870080108. PMID: 8093548.
741. Levin OS, Chimagomedova ASh, Skripkina NA, Lyashenko EA, Babkina OV. Nonmotor Symptoms in Vascular and Other Secondary Parkinsonism. International review of neurobiology. 2017;134:1303-1334.
742. Карабань И.Н. Сосудистый паркинсонизм: возможность и/или объективная реальность // Междунар. неврол. журн.; МНЖ. 2016. №3 (81). URL: https://cyberleninka.ru/article/n/sosudistyy-parkinsonizm-vozmozhnost-i-ili-obektivnaya- realnost (дата обращения: 02.10.2021).
743. Юдина, В.В. Диагностика и лечение сосудистого паркинсонизма / В. В. Юдина, О. Н. Воскресенская, Г. К. Юдина // Саратовский научно-медицинский журнал. – 2010. – Т. 6. – № 1. C. 120-123.
744. Coon E.A., Ahlskog J.E. My Treatment Approach to Multiple System Atrophy //Mayo Clinic Proceedings. – Elsevier, 2021. – Т. 96. – №. 3. C. 708-719.
745. Coon E.A., Ahlskog J.E. My Treatment Approach to Multiple System Atrophy //Mayo Clinic Proceedings. – Elsevier, 2021. – Т. 96. – №. 3. C. 708-719
746. Rondot P., Ziegler M. Activity and acceptability of piribedil in Parkinson's disease: a multicentre study //Journal of neurology. – 1992. – Т. 239. – №. 1. C. S28-S34.
747. Pena E. et al. Antidepressants in Parkinson's disease. Recommendations by the movement disorder study group of the Neurological Association of Madrid //Neurología (English Edition). – 2018. – Т. 33. – №. 6. C. 395-402.